Real-World Effectiveness of Sotrovimab in Ambulatory Patients With COVID-19: A Retrospective Cohort Study Using a Large Administrative Claims Database in the United States
Open Access
- 6 February 2025
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 47 (4) , 284-292
Abstract
No abstract availableKeywords
Funding Information
- VIR Biotechnology Inc
- GlaxoSmithKline (218263, 219589)
This publication has 28 references indexed in Scilit:
- Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C)Clinical Drug Investigation, 2024
- Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5International Journal of Infectious Diseases, 2023
- Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort studyThe Lancet Infectious Diseases, 2023
- Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USAInfectious Diseases and Therapy, 2023
- Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19Infectious Diseases and Therapy, 2022
- Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19JAMA, 2022
- A Novel Approach to Equitable Distribution of Scarce TherapeuticsChest, 2021
- Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deploymentJACEP Open, 2021
- Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 casesHeliyon, 2020
- Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling studyThe Lancet Global Health, 2020